-
2024-511458-32-00
5
2025-06-15
Ulcerative colitis
-
2024-517032-22-00
5
2025-06-10
Immune system diseases.
-
2024-512659-19-00
10
2025-03-31
Advanced Melanoma
-
2024-514737-37-00
5
2025-03-06
Neurodermatitis
-
2022-501332-42-00
5
2025-02-26
Relapsing Remitting Multiple Sclerosis
-
2023-503188-40-00
5
2025-01-06
Active Ulcerative Colitis or Crohn’s Disease
-
2023-507717-94-00
5
2024-12-06
Deep partial and full-thickness burns
-
2023-506091-27-00
4
2024-09-19
Achondroplasia in Children and Adolescents
-
2023-507129-40-00
4
2024-08-06
interstitial lung disease secondary to systemic sclerosis (SSc-ILD)
-
2023-505000-27-01
4
2023-12-29
newly diagnosed pediatric FLT3-ITD positive and NPM1 wild-type AML
-
2022-501099-24-00
5
2023-12-22
Migraine
-
2022-502286-16-00
5
2023-10-27
Primary Generalized Tonic-Clonic Seizures
-
2022-500266-10-00
5
2023-06-13
Recessive Dystrophic Epidermolysis Bullosa(RDEB) and Junctional Epider
-
2022-501709-11-00
5
2023-06-06
Isocitrate deshydrogenase1 mutation-positive (IDH1m) acute myeloid leu
-
2022-500488-10-00
5
2022-12-19
Fabry Disease and Amenable GLA Variants and Severe Renal Impairment or
-
2022-502503-30-00
5
2022-12-15
Acute lymphoblastic leukemia
-
2023-506414-46-00
5
2022-04-22
High risk patients defined as having at least one of the following ris
-
2024-511686-11-00
5
2021-10-05
Multiple Sclerosis in pediatric patients
-
2023-509628-16-00
5
2026-05-07
Small Cell Lung Cancer (SCLC)
-
2025-523260-20-00
4
2026-04-28
type 2 diabetes
-
2024-513174-22-00
4
2026-04-14
Atrophic Age-related Macular Degeneration (AMD)
-
2025-522046-42-00
5
2026-03-24
Colonic disease
-
2025-522873-12-00
5
2026-02-24
ER+, HER2- Advanced Breast Cancer
-
2025-522960-34-00
5
2026-02-09
Established cardiovascular disease